Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market
One year post launch, Vertex’s (Nasdaq: VRTX) Incivek (telaprevir) and Merck & Co (NYSE: MRK) and Roche’s (ROG: SIX) Victrelis (boceprevir) have staked their claim as the standard of care in US genotype 1 hepatitis C virus (HCV) patients, with 96% of surveyed physicians reporting trial with at least one of the protease inhibitors (PIs), according to a new report from BioTrends, a Decision Resources unit.
According to the recently released LaunchTrends: Incivek and Victrelis, Wave 4 report, since their launch one year ago, the PIs have penetrated over three-quarters of the genotype 1 HCV market. Though share for each PI has significantly increased since prior waves, current physician estimates have Incivek accounting for significantly more of the US PI market than Victrelis.
Physicians report higher satisfaction with Incivek
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze